JAZZ – Jazz Pharmaceuticals plc
JAZZ
$199.44Name : Jazz Pharmaceuticals plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $12,277,288,960.00
EPSttm : -5.84
Jazz Pharmaceuticals plc
$199.44
JAZZ — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
11.19
Margin Of Safety %
-5
Put/Call OI Ratio
0.67
EPS Next Q Diff
0.26
EPS Last/This Y
29.9
EPS This/Next Y
1.02
Price
195.19
Target Price
225.44
Analyst Recom
1.47
Performance Q
21.21
Upside
-139.7%
Beta
0.24
Ticker: JAZZ
17 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-17 | JAZZ | 181.29 | 1.06 | 3.91 | 13894 |
| 2026-03-18 | JAZZ | 180.45 | 1.06 | 0.52 | 13985 |
| 2026-03-19 | JAZZ | 181.72 | 1.06 | 1.26 | 13984 |
| 2026-03-20 | JAZZ | 180.64 | 1.06 | 2.17 | 13845 |
| 2026-03-23 | JAZZ | 182.28 | 0.75 | 0.86 | 5967 |
| 2026-03-24 | JAZZ | 185 | 0.76 | 5.13 | 6013 |
| 2026-03-25 | JAZZ | 189.06 | 0.78 | 0.03 | 6093 |
| 2026-03-26 | JAZZ | 189 | 0.73 | 0.73 | 6335 |
| 2026-03-27 | JAZZ | 182.61 | 0.74 | 1.23 | 6450 |
| 2026-03-30 | JAZZ | 182.99 | 0.77 | 0.45 | 6692 |
| 2026-03-31 | JAZZ | 189.03 | 0.76 | 1.68 | 6798 |
| 2026-04-01 | JAZZ | 188.29 | 0.76 | 1.12 | 6801 |
| 2026-04-02 | JAZZ | 187 | 0.79 | 3.54 | 6844 |
| 2026-04-06 | JAZZ | 186.92 | 0.81 | 0.06 | 6905 |
| 2026-04-08 | JAZZ | 195.96 | 0.74 | 0.05 | 7238 |
| 2026-04-09 | JAZZ | 198.18 | 0.69 | 0.30 | 7612 |
| 2026-04-13 | JAZZ | 195.29 | 0.67 | 0.22 | 7925 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
17 items
«
‹
Current Page1 of 1
›
»
18 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-17 | JAZZ | 181.29 | 172.0 | 1906.4 | 23.83 |
| 2026-03-18 | JAZZ | 180.45 | 172.0 | 1905.2 | 23.83 |
| 2026-03-19 | JAZZ | 181.83 | 172.0 | 1526.3 | 23.83 |
| 2026-03-20 | JAZZ | 180.62 | 172.0 | 1513.9 | 23.83 |
| 2026-03-23 | JAZZ | 182.22 | 172.0 | 1527.2 | 23.83 |
| 2026-03-24 | JAZZ | 184.92 | 174.1 | 1531.9 | 23.92 |
| 2026-03-25 | JAZZ | 188.98 | 174.1 | 1538.2 | 23.92 |
| 2026-03-26 | JAZZ | 189.21 | 174.1 | 1520.3 | 23.92 |
| 2026-03-27 | JAZZ | 182.61 | 174.1 | 1489.6 | 23.92 |
| 2026-03-30 | JAZZ | 183.06 | 174.1 | 1521.6 | 23.92 |
| 2026-03-31 | JAZZ | 188.94 | 174.4 | 1547.4 | 23.93 |
| 2026-04-01 | JAZZ | 188.38 | 174.4 | 1516.6 | 23.93 |
| 2026-04-02 | JAZZ | 186.87 | 174.4 | 1512.7 | 23.93 |
| 2026-04-06 | JAZZ | 186.87 | 174.4 | 1519.3 | 23.93 |
| 2026-04-07 | JAZZ | 190.98 | 174.4 | 1538.7 | 23.93 |
| 2026-04-09 | JAZZ | 198.14 | 174.4 | 1529.5 | 23.93 |
| 2026-04-10 | JAZZ | 194.17 | 179.5 | 1502.5 | 24.06 |
| 2026-04-13 | JAZZ | 195.19 | 179.5 | 1524.2 | 24.06 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
18 items
«
‹
Current Page1 of 1
›
»
19 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-17 | JAZZ | -5.89 | 0.95 | 10.29 |
| 2026-03-18 | JAZZ | -5.89 | 0.95 | 10.29 |
| 2026-03-19 | JAZZ | -5.89 | 0.95 | 10.29 |
| 2026-03-20 | JAZZ | -5.89 | 0.95 | 10.29 |
| 2026-03-23 | JAZZ | -5.89 | 0.99 | 10.29 |
| 2026-03-24 | JAZZ | -5.89 | 0.99 | 10.29 |
| 2026-03-25 | JAZZ | -5.89 | 0.99 | 10.57 |
| 2026-03-26 | JAZZ | -5.89 | 0.99 | 10.57 |
| 2026-03-27 | JAZZ | -5.89 | 0.99 | 10.57 |
| 2026-03-30 | JAZZ | -5.89 | 0.99 | 10.57 |
| 2026-03-31 | JAZZ | -5.89 | 0.99 | 10.57 |
| 2026-04-01 | JAZZ | -5.89 | 0.99 | 10.57 |
| 2026-04-02 | JAZZ | -5.89 | 0.99 | 10.57 |
| 2026-04-06 | JAZZ | -5.90 | 0.99 | 10.57 |
| 2026-04-07 | JAZZ | -5.90 | 0.99 | 10.57 |
| 2026-04-08 | JAZZ | -5.90 | 0.99 | 10.57 |
| 2026-04-09 | JAZZ | -5.90 | 0.99 | 10.57 |
| 2026-04-10 | JAZZ | -5.90 | 0.99 | 10.57 |
| 2026-04-13 | JAZZ | -5.90 | 1.06 | 11.19 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
19 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
5.76
Avg. EPS Est. Current Quarter
4.61
Avg. EPS Est. Next Quarter
6.02
Insider Transactions
-5.9
Institutional Transactions
1.06
Beta
0.24
Average Sales Estimate Current Quarter
977
Average Sales Estimate Next Quarter
1106
Fair Value
185.5
Quality Score
50
Growth Score
68
Sentiment Score
98
Actual DrawDown %
2.5
Max Drawdown 5-Year %
-47.5
Target Price
225.44
P/E
Forward P/E
7.77
PEG
0.16
P/S
2.82
P/B
2.78
P/Free Cash Flow
9.27
EPS
-5.97
Average EPS Est. Cur. Y
24.06
EPS Next Y. (Est.)
25.07
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-8.35
Relative Volume
1.02
Return on Equity vs Sector %
-35.6
Return on Equity vs Industry %
-19
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.23
EBIT Estimation
1524.2
◆
JAZZ
Healthcare
$195.31
📉
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
0/20
Pullback
8/25
Volume
4/15
Valuation
9/20
TP/AR
4/10
Options
6/10
RSI
62.8
Range 1M
78.9%
Sup Dist
2.2%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
6/25
Growth
19/30
Estimates
5/20
Inst/Vol
8/15
Options
8/10
EPS Yr
187.3%
EPS NY
4.5%
52W%
95.5%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+35% upside
Quality
8/30
Valuation
15/30
Growth
13/25
Stability
4/10
LT Trend
1/5
Upside
+35%
Quality
50
MoS
-5%
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 2890
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
JAZZ
Latest News
—
Caricamento notizie per JAZZ…
stock quote shares JAZZ – Jazz Pharmaceuticals plc Stock Price stock today
news today JAZZ – Jazz Pharmaceuticals plc stock forecast ,stock prediction 2023 2024 2025
marketwatch JAZZ – Jazz Pharmaceuticals plc yahoo finance google finance
stock history JAZZ – Jazz Pharmaceuticals plc invest stock market
stock prices JAZZ premarket after hours
ticker JAZZ fair value insiders trading
JAZZ
$199.19Name : Jazz Pharmaceuticals plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $12,262,206,464.00
EPSttm : -5.84
Jazz Pharmaceuticals plc
$199.19
JAZZ — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
11.19
Margin Of Safety %
-5
Put/Call OI Ratio
0.67
EPS Next Q Diff
0.26
EPS Last/This Y
29.9
EPS This/Next Y
1.02
Price
195.19
Target Price
225.44
Analyst Recom
1.47
Performance Q
21.21
Upside
-139.7%
Beta
0.24
Ticker: JAZZ
17 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-17 | JAZZ | 181.29 | 1.06 | 3.91 | 13894 |
| 2026-03-18 | JAZZ | 180.45 | 1.06 | 0.52 | 13985 |
| 2026-03-19 | JAZZ | 181.72 | 1.06 | 1.26 | 13984 |
| 2026-03-20 | JAZZ | 180.64 | 1.06 | 2.17 | 13845 |
| 2026-03-23 | JAZZ | 182.28 | 0.75 | 0.86 | 5967 |
| 2026-03-24 | JAZZ | 185 | 0.76 | 5.13 | 6013 |
| 2026-03-25 | JAZZ | 189.06 | 0.78 | 0.03 | 6093 |
| 2026-03-26 | JAZZ | 189 | 0.73 | 0.73 | 6335 |
| 2026-03-27 | JAZZ | 182.61 | 0.74 | 1.23 | 6450 |
| 2026-03-30 | JAZZ | 182.99 | 0.77 | 0.45 | 6692 |
| 2026-03-31 | JAZZ | 189.03 | 0.76 | 1.68 | 6798 |
| 2026-04-01 | JAZZ | 188.29 | 0.76 | 1.12 | 6801 |
| 2026-04-02 | JAZZ | 187 | 0.79 | 3.54 | 6844 |
| 2026-04-06 | JAZZ | 186.92 | 0.81 | 0.06 | 6905 |
| 2026-04-08 | JAZZ | 195.96 | 0.74 | 0.05 | 7238 |
| 2026-04-09 | JAZZ | 198.18 | 0.69 | 0.30 | 7612 |
| 2026-04-13 | JAZZ | 195.29 | 0.67 | 0.22 | 7925 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
17 items
«
‹
Current Page1 of 1
›
»
18 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-17 | JAZZ | 181.29 | 172.0 | 1906.4 | 23.83 |
| 2026-03-18 | JAZZ | 180.45 | 172.0 | 1905.2 | 23.83 |
| 2026-03-19 | JAZZ | 181.83 | 172.0 | 1526.3 | 23.83 |
| 2026-03-20 | JAZZ | 180.62 | 172.0 | 1513.9 | 23.83 |
| 2026-03-23 | JAZZ | 182.22 | 172.0 | 1527.2 | 23.83 |
| 2026-03-24 | JAZZ | 184.92 | 174.1 | 1531.9 | 23.92 |
| 2026-03-25 | JAZZ | 188.98 | 174.1 | 1538.2 | 23.92 |
| 2026-03-26 | JAZZ | 189.21 | 174.1 | 1520.3 | 23.92 |
| 2026-03-27 | JAZZ | 182.61 | 174.1 | 1489.6 | 23.92 |
| 2026-03-30 | JAZZ | 183.06 | 174.1 | 1521.6 | 23.92 |
| 2026-03-31 | JAZZ | 188.94 | 174.4 | 1547.4 | 23.93 |
| 2026-04-01 | JAZZ | 188.38 | 174.4 | 1516.6 | 23.93 |
| 2026-04-02 | JAZZ | 186.87 | 174.4 | 1512.7 | 23.93 |
| 2026-04-06 | JAZZ | 186.87 | 174.4 | 1519.3 | 23.93 |
| 2026-04-07 | JAZZ | 190.98 | 174.4 | 1538.7 | 23.93 |
| 2026-04-09 | JAZZ | 198.14 | 174.4 | 1529.5 | 23.93 |
| 2026-04-10 | JAZZ | 194.17 | 179.5 | 1502.5 | 24.06 |
| 2026-04-13 | JAZZ | 195.19 | 179.5 | 1524.2 | 24.06 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
18 items
«
‹
Current Page1 of 1
›
»
19 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-17 | JAZZ | -5.89 | 0.95 | 10.29 |
| 2026-03-18 | JAZZ | -5.89 | 0.95 | 10.29 |
| 2026-03-19 | JAZZ | -5.89 | 0.95 | 10.29 |
| 2026-03-20 | JAZZ | -5.89 | 0.95 | 10.29 |
| 2026-03-23 | JAZZ | -5.89 | 0.99 | 10.29 |
| 2026-03-24 | JAZZ | -5.89 | 0.99 | 10.29 |
| 2026-03-25 | JAZZ | -5.89 | 0.99 | 10.57 |
| 2026-03-26 | JAZZ | -5.89 | 0.99 | 10.57 |
| 2026-03-27 | JAZZ | -5.89 | 0.99 | 10.57 |
| 2026-03-30 | JAZZ | -5.89 | 0.99 | 10.57 |
| 2026-03-31 | JAZZ | -5.89 | 0.99 | 10.57 |
| 2026-04-01 | JAZZ | -5.89 | 0.99 | 10.57 |
| 2026-04-02 | JAZZ | -5.89 | 0.99 | 10.57 |
| 2026-04-06 | JAZZ | -5.90 | 0.99 | 10.57 |
| 2026-04-07 | JAZZ | -5.90 | 0.99 | 10.57 |
| 2026-04-08 | JAZZ | -5.90 | 0.99 | 10.57 |
| 2026-04-09 | JAZZ | -5.90 | 0.99 | 10.57 |
| 2026-04-10 | JAZZ | -5.90 | 0.99 | 10.57 |
| 2026-04-13 | JAZZ | -5.90 | 1.06 | 11.19 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
19 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
5.76
Avg. EPS Est. Current Quarter
4.61
Avg. EPS Est. Next Quarter
6.02
Insider Transactions
-5.9
Institutional Transactions
1.06
Beta
0.24
Average Sales Estimate Current Quarter
977
Average Sales Estimate Next Quarter
1106
Fair Value
185.5
Quality Score
50
Growth Score
68
Sentiment Score
98
Actual DrawDown %
2.5
Max Drawdown 5-Year %
-47.5
Target Price
225.44
P/E
Forward P/E
7.77
PEG
0.16
P/S
2.82
P/B
2.78
P/Free Cash Flow
9.27
EPS
-5.97
Average EPS Est. Cur. Y
24.06
EPS Next Y. (Est.)
25.07
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-8.35
Relative Volume
1.02
Return on Equity vs Sector %
-35.6
Return on Equity vs Industry %
-19
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.23
EBIT Estimation
1524.2
◆
JAZZ
Healthcare
$195.31
📉
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
0/20
Pullback
8/25
Volume
4/15
Valuation
9/20
TP/AR
4/10
Options
6/10
RSI
62.8
Range 1M
78.9%
Sup Dist
2.2%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
6/25
Growth
19/30
Estimates
5/20
Inst/Vol
8/15
Options
8/10
EPS Yr
187.3%
EPS NY
4.5%
52W%
95.5%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+35% upside
Quality
8/30
Valuation
15/30
Growth
13/25
Stability
4/10
LT Trend
1/5
Upside
+35%
Quality
50
MoS
-5%
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 2890
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
JAZZ
Latest News
—
Caricamento notizie per JAZZ…
stock quote shares JAZZ – Jazz Pharmaceuticals plc Stock Price stock today
news today JAZZ – Jazz Pharmaceuticals plc stock forecast ,stock prediction 2023 2024 2025
marketwatch JAZZ – Jazz Pharmaceuticals plc yahoo finance google finance
stock history JAZZ – Jazz Pharmaceuticals plc invest stock market
stock prices JAZZ premarket after hours
ticker JAZZ fair value insiders trading